CIDRAP newsletters options
"These findings imply that the pandemic may substantially contribute to the world dementia burden."
Continuing the corticosteroid dexamethasone after hospital release didn't benefit COVID-19 patients who didn't complete the 10-day drug regimen during their stay, finds a study published yesterday in JAMA Network Open.
The imaging differences between COVID-19 and non-COVID patients were modest, about 2%.
Fully 92% of side effects during the first 6 months of the US vaccine rollout were mild and short-lived.
Different approaches may be needed in the future, experts say, such as vaccines that target a specific variant.
China has reported to more H5N6 avian flu infections in humans, both fatal in people who were sick in November and died in early December, Hong Kong's Centre for Health Protection (CHP) said in a statement today.
Three percent of 10,403 adults with COVID-19 pneumonia were diagnosed as having new-onset dementia after a median of 182 days, a significantly higher proportion than that observed with other types of pneumonia, finds a study yesterday in Open Forum Infectious Diseases.
The CDC says the risk to humans is low, but people with elevated exposure may be at higher risk.
Concerns are growing that continued spread could create COVID-19 virus reservoirs in animals.
Social determinants of health tied to COVID-19 death rates vary by race and community type, a new study finds.
The roadmap advises against school closings, lobbies for more tests, and details when restrictions should lift.
Hospitalized COVID-19 patients with congenital heart defects (CHDs) were more likely to be admitted to an intensive care unit (ICU), require invasive mechanical ventilation (IMV), and die than those without CHDs in the first 11 months of the pandemic, suggests a study published today in Circulation.
A new joint report on antimicrobial resistance (AMR) in European Union/European Economic Activity (EU/EEA) countries is calling for concerted action to address the problem from a One Health perspective.
The CDC says 90% of Americans are in areas with low or medium levels of COVID-19.
Death rates were 22% to 25% lower despite a 41% ICU rate, compared with 18% in other hospitals.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
The estimated effectiveness of the Pfizer/BioNTech COVID-19 vaccine against infection in US adolescents was 91%, with 93% protection against symptomatic illness and 85% against asymptomatic disease amid the Delta SARS-CoV-2 surge in Connecticut, finds a study published yesterday in JAMA Network Open.
An analysis of data on bloodstream infections (BSIs) from countries in the World Health Organization (WHO) Eastern Mediterranean Region shows a high prevalence of antimicrobial resistance (AMR) in the region and limited capacity to prevent the emergence and spread of resistant pathogens, WHO researchers reported yesterday in Emerging Infectious Diseases.
The gap between the groups did not close during the Delta and Omicron surges, a new study finds.
Experts call on nations to cut antimicrobial discharge from manufacturers, farms, hospitals, and other sources.
